Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-453 | TGX221 | PI3Kb | PI3K/mTOR | 15.3342 | 0.8281 | -0.0281 | 0.0177 | 4.9457 | 12.4514 | 0.62788 |
HCC70 | Palbociclib | CDK4/6 | Cell cycle | Inf | 0.9361 | -0.0281 | -0.0013 | 0.0000 | Inf | -0.054738 |
PDXHCI002 | PF-4708671 | p70S6K | PI3K/mTOR | Inf | 0.8732 | -0.0268 | -0.0011 | 0.0000 | Inf | 0.45924 |
BT-20 | A-1210477 | Mcl-1 | Misc | 14.9935 | 0.8209 | -0.0262 | 0.0007 | 4.9994 | 12.3309 | 0.67398 |
HCC1954 | A-1210477 | Mcl-1 | Misc | Inf | 0.8844 | -0.0259 | 0.0076 | 0.0000 | Inf | 0.43063 |
HCC38 | PF-4708671 | p70S6K | PI3K/mTOR | Inf | 0.9760 | -0.0258 | -0.0006 | 0.0000 | Inf | -0.90907 |
HCC38 | TGX221 | PI3Kb | PI3K/mTOR | Inf | 0.9515 | -0.0246 | 0.0013 | 0.0000 | Inf | -0.17011 |
SUM1315MO2 | A-1210477 | Mcl-1 | Misc | Inf | 0.7399 | -0.0234 | -0.0009 | 3.9393 | 9.1387 | 0.79269 |
CAL-85-1 | PF-4708671 | p70S6K | PI3K/mTOR | Inf | 1.0208 | -0.0232 | 0.0035 | 0.0000 | Inf | -0.61108 |
HCC70 | PF-4708671 | p70S6K | PI3K/mTOR | Inf | 0.9348 | -0.0227 | 0.0035 | 0.0000 | Inf | 0.040075 |
BT-549 | ABT-737 | Bcl2/XL | Misc | Inf | 0.9359 | -0.0225 | 0.0062 | 0.0000 | Inf | 0.067883 |
SUM149PT | TGX221 | PI3Kb | PI3K/mTOR | Inf | 1.0138 | -0.0216 | 0.0006 | 0.0000 | Inf | -4.4171 |
MDA-MB-468 | Palbociclib | CDK4/6 | Cell cycle | Inf | 1.0457 | -0.0214 | 0.0005 | 0.0000 | Inf | -0.58792 |
HCC1806 | PF-4708671 | p70S6K | PI3K/mTOR | Inf | 1.0500 | -0.0207 | -0.0033 | 0.0000 | Inf | -0.67606 |
HCC1428 | A-1210477 | Mcl-1 | Misc | Inf | 0.8155 | -0.0207 | 0.0026 | 4.9615 | 5.2131 | 0.71606 |
PDXHCI002 | TGX221 | PI3Kb | PI3K/mTOR | Inf | 0.8545 | -0.0204 | -0.0045 | 5.0000 | 4.5889 | 0.61889 |
CAL-120 | TGX221 | PI3Kb | PI3K/mTOR | Inf | 1.0198 | -0.0168 | -0.0059 | 0.0000 | Inf | -0.45144 |
MDA-MB-134-VI | Cabozantinib | VEGFR2/MET | RTK | 10.9194 | 0.6362 | -0.0167 | -0.0063 | 5.0000 | 12.725 | 0.88168 |
HCC1806 | TGX221 | PI3Kb | PI3K/mTOR | Inf | 0.9819 | -0.0154 | 0.0035 | 0.0000 | Inf | -0.19348 |
SK-BR-3 | ABT-737 | Bcl2/XL | Misc | Inf | 0.9470 | -0.0148 | 0.0045 | 0.0000 | Inf | 0.12804 |
HCC1954 | Cabozantinib | VEGFR2/MET | RTK | 10.9106 | 0.6390 | -0.0135 | -0.0074 | 5.0000 | 13.0234 | 0.87916 |
MCF 10A | Cabozantinib | VEGFR2/MET | RTK | 25.9104 | 0.8434 | -0.0114 | 0.0040 | 4.9998 | 11.7694 | 0.81226 |
HCC1419 | Cabozantinib | VEGFR2/MET | RTK | 10.7779 | 0.6224 | -0.0111 | -0.0016 | 5.0000 | 12.9768 | 0.90031 |
CAL-51 | TGX221 | PI3Kb | PI3K/mTOR | Inf | 0.9105 | -0.0094 | 0.0003 | 0.0000 | Inf | 0.56048 |
HCC1954 | PF-4708671 | p70S6K | PI3K/mTOR | Inf | 0.8349 | -0.0093 | -0.0064 | 1.3800 | 7.2097 | 0.65841 |